Removal of Tobramycin During Plasma Exchange Therapy
Authors: ROBERT APPELGATE
Journal: Annals of Internal Medicine (1981)

Letters1 June 1981Removal of Tobramycin During Plasma Exchange TherapyROBERT APPELGATE, M.D., DOUGLAS SCHWARTZ, M.D., WILLIAM M. BENNETT, M.D.ROBERT APPELGATE, M.D.Search for more papers by this author, DOUGLAS SCHWARTZ, M.D.Search for more papers by this author, WILLIAM M. BENNETT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-6-820_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Plasma exchange therapy has achieved widespread acceptance as a therapeutic modality in a number of serious illnessses such as Goodpasture's syndrome, rapidly progressive glomerulonephritis, and thrombotic thrombocytopenic purpura (1). A recent report has emphasized the frequent life-threatening bacterial infections that may complicate this form of therapy (2). We recently studied tobramycin concentrations during plasma exchange treatments for thrombotic thrombocytopenic purpura. Dosage supplementation is needed to maintain therapeutic plasma concentrations.A 63-year-old woman had a 6-month history of progressive muscle tenderness and weakness. Muscle biopsy showed inflammatory myositis with perivascular lymphocytic infiltration. Hematocrit, hemoglobin, urinalysis, and renal function...References1. LOCKWOODPETERS CD. Plasma exchange in glomerulonephritis and related vasculitides. Annu Rev Med. 1980;31:167-79. CrossrefMedlineGoogle Scholar2. WINGBRUNSFRALEYSEGELADLER EJDDS. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA. 1980;244:2423-6. CrossrefMedlineGoogle Scholar3. BENNETTMUTHERPARKER WRR. Drug therapy in renal failure: dosing guidelines for adults: Part I: Antimicrobial agents, analgesics. Ann Intern Med. 1980;93 (Part 1):62-89. LinkGoogle Scholar4. MYERSDEFEHRBENNETTPORTEROLSEN DJWGG. Gentamicin binding to human serum and plasma proteins. Clin Pharmacol Ther. 1978;:23:.356-60. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Oregon Health Sciences Center Portland OR 97201 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug Dosing in Patients Undergoing Therapeutic Plasma ExchangeTherapeutic Plasma ExchangePlasmapheresis in Acute Intoxication and PoisoningMedications in Patients Treated With Therapeutic Plasma Exchange: Prescription Dosage, Timing, and Drug OverdosePlasmapheresis in Acute Intoxication and PoisoningDrug Removal by Plasmapheresis: An Evidence-Based ReviewTherapeutic Plasma ExchangeExtracorporeal removal of antimicrobials during plasmapheresisVancomycin Removal during a Plasma Exchange TransfusionTherapeutic apheresis in renal and metabolic diseasesPharmacokinetics of teicoplanin during plasma exchangeRemoval of Vancomycin during PlasmapheresisDiclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patientsPlasmapheresis: Technique and complicationsPharmacokinetics of Paracetamol, Diclofenac and Vidarabine during Plasma ExchangeVitamin status in patients undergoing single or multiple plasmapheresis.Phenytoin removal during plasma exchangeCurrent status of plasmapheresis in toxicologyA Pharmacokinetic Evaluation of the Effect of Plasma Exchange on Tobramycin Disposition 1 June 1981Volume 94, Issue 6Page: 820-821KeywordsAttentionBlood plasmaGlomerulonephritisHematocritHemoglobinMuscle biopsiesMyalgiaMyositisThrombotic thrombocytopenic purpura ePublished: 1 December 2008 Issue Published: 1 June 1981 PDF downloadLoading ...